Results of 2018 — a word from CEO

Dear colleagues and friends!

In anticipation of the upcoming new 2019, we would like to take summarise results of our work in 2018 and share with you some our plans.

2018 was a special year for us. This year, the ARNA Genomics project became five years old, a significant milestone for any startup, especially in the biotechnology sector.

Over the past year, our team has become stronger with joining of new employees and advisers. Joining of Mr. Charles Cantor as a shareholder and member of the Board of Directors has become for us an essential intellectual and scientific milestone.

In the spring, we have opened a second research laboratory and were able to enter the market for personal genetic research, which required the concentration of efforts of many people! This step showed the operational potential of our team.

Since the beginning of the year, we have conducted research on the ARNA Breast test for the early detection of breast cancer in a clinical setting. In November, we have obtained and presented brilliant interim results during the Russian Oncological Congress. We plan to complete this study at the very beginning of 2019.

We are also thrilled to announce that we are currently in the process of deal closing with a new investor, as a result we will be able to significantly expand our presence in Europe and the world next year, as well as expand the company’s activities in terms of further developments in the field of liquid biopsy.

We sincerely thank everyone who was with us this year! Happy New Year! Let it be bright, filled with events and extraordinary achievements!

Sincerely yours,

Egor Melnikov

CEO and Founder